Clinical profile, associated events and safety of vericiguat in a real-world cohort: The VERITA study.
Mario Galván RuizMiguel Fernández de Sanmamed GirónMaría Del Val Groba MarcoLorena Rojo JorgeClaudia Peña SaavedraElvira Martín BouRubén Andrade GuerraEduardo Caballero DortaAntonio García QuintanaPublished in: ESC heart failure (2024)
In clinical practice, treatment with vericiguat is associated with substantial improvements in functional class and quality of life and a reduction in hospitalizations for HF, with a low risk of adverse effects.